Tumor Targeting

License obtained for heat-activated gene therapy

Published in Drug Week, October 17th, 2003

Celsion Corp. (CLN) announced that it has acquired exclusive worldwide commercialization rights to a package of proprietary gene therapy technologies developed by scientists at the U.S. National Institutes of Health (NIH).

The technology is covered by a pending NIH patent application, detailing the use of heat energy to activate and control gene therapy and the construction of various heat-sensitive "Gene Therapy Constructs." Under the license agreement, Celsion has the exclusive rights to develop heat-sensitive gene therapy products activated by microwave heat energy.

Celsion believes that its proprietary microwave-focused heating technology, which...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2003-10-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry